XML 149 R36.htm IDEA: XBRL DOCUMENT v3.23.2

Business Segments (Tables)

3 Months Ended

Jun. 30, 2023

Segment Reporting [Abstract]

Operating and Reportable Segments

The tables below summarize information about our reportable segments.

			Three Months Ended June 30, 2023
(In thousands)			North American OTC Healthcare						International OTC Healthcare												Consolidated
Total segment revenues*			$	246,143					$	33,166											$	279,309
Cost of sales			110,076						14,560												124,636
Gross profit			136,067						18,606												154,673
Advertising and marketing			31,401						4,830												36,231
Contribution margin			$	104,666					$	13,776											118,442
Other operating expenses																					33,248
Operating income																					$	85,194
* Intersegment revenues of $1.4 million were eliminated from the North American OTC Healthcare segment.

			Three Months Ended June 30, 2022
(In thousands)			North American OTC Healthcare						International OTC Healthcare												Consolidated
Total segment revenues*			$	242,518					$	34,541											$	277,059
Cost of sales			102,921						14,019												116,940
Gross profit			139,597						20,522												160,119
Advertising and marketing			35,412						4,539												39,951
Contribution margin			$	104,185					$	15,983											120,168
Other operating expenses																					33,154
Operating income																					$	87,014
* Intersegment revenues of $0.5 million were eliminated from the North American OTC Healthcare segment.

Revenues from Similar Product Groups

The tables below summarize information about our segment revenues from similar product groups.

			Three Months Ended June 30, 2023
(In thousands)			North American OTC Healthcare						International OTC Healthcare												Consolidated
Analgesics			$	27,182					$	842											$	28,024
Cough & Cold			20,374						6,052												26,426
Women's Health			54,955						4,956												59,911
Gastrointestinal			44,681						12,910												57,591
Eye & Ear Care			39,471						4,021												43,492
Dermatologicals			34,678						1,338												36,016
Oral Care			21,726						3,022												24,748
Other OTC			3,076						25												3,101
Total segment revenues			$	246,143					$	33,166											$	279,309

			Three Months Ended June 30, 2022
(In thousands)			North American OTC Healthcare						International OTC Healthcare												Consolidated
Analgesics			$	27,797					$	453											$	28,250
Cough & Cold			21,592						6,271												27,863
Women's Health			61,184						4,867												66,051
Gastrointestinal			40,067						14,027												54,094
Eye & Ear Care			38,611						4,736												43,347
Dermatologicals			29,455						1,006												30,461
Oral Care			20,975						3,170												24,145
Other OTC			2,837						11												2,848
Total segment revenues			$	242,518					$	34,541											$	277,059

X

- Definition

Tabular disclosure of entity-wide revenues from external customers for each product or service or each group of similar products or services if the information is not provided as part of the reportable operating segment information.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 40
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482810/280-10-50-40

+ Details

Name:	us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock
Namespace Prefix:	us-gaap_
Data Type:	dtr-types:textBlockItemType
Balance Type:	na
Period Type:	duration

X

- Definition

Tabular disclosure of the profit or loss and total assets for each reportable segment. An entity discloses certain information on each reportable segment if the amounts (a) are included in the measure of segment profit or loss reviewed by the chief operating decision maker or (b) are otherwise regularly provided to the chief operating decision maker, even if not included in that measure of segment profit or loss.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Name Accounting Standards Codification
-Topic 350
-SubTopic 20
-Section 50
-Paragraph 1
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482573/350-20-50-1

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 25
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482810/280-10-50-25

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 22
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482810/280-10-50-22

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 30
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482810/280-10-50-30

+ Details

Name:	us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock
Namespace Prefix:	us-gaap_
Data Type:	dtr-types:textBlockItemType
Balance Type:	na
Period Type:	duration

X

- References

No definition available.

+ Details

Name:	us-gaap_SegmentReportingAbstract
Namespace Prefix:	us-gaap_
Data Type:	xbrli:stringItemType
Balance Type:	na
Period Type:	duration